Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, and other mental health disorders. The company's product candidates include COMP360, BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, a transmucosal film in Phase 2 clinical study; and ELE-101, a serotonergic psychedelic for the treatment of treatment resistant depression. It also EMP-01, an oral formulation of an R-MDMA that Is in phase 2 clinical study; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, the company offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, for the treatment of generalize anxiety disorder. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Atai Beckley N.V

Analysts are intrested in these 5 stocks: ( ($WDAY) ), ( ($BEP) ), ( ($JBLU) ), ( ($ENVX) ) and ( ($ATAI) ). Here is a breakdown of their recent


Workday, Brookfield, JetBlue, Enovix, Atai Trending With Analysts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Sil...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATAI	$7.31	+0.34%	5.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATAI	$7.31	+0.3%	5.70M
3
4
5
6

ATAI

Get Atai Beckley N.V Data in Excel

Get Atai Beckley N.V Data in Excel